Skip to main content

Table 3 Availability of outcome data by trial subgroup

From: Delays in reporting and publishing trial results during pandemics: cross sectional analysis of 2009 H1N1, 2014 Ebola, and 2016 Zika clinical trials

Trial characteristic Total trials; n Registry has results within 12 months of trial completion; n (%) Months elapsed from completion to results in registry;
median (IQR)
Publication within 24 months of trial completion; n (%) Months elapsed from completion to publication; median (IQR)
Total 333 15 (5%) 42 (16–76) 129 (39%) 21 (9–34)
Infection
  H1N1 261 11 (4%) 45 (18–78) 94 (36%) 23 (12–34)
  Ebola 60 4 (7%) 16 (12–43) 29 (48%) 11 (-2–34)
  Zika 12 0 (0%)   6 (50%) -3 (-11–18)
Funding Source
  Industry 206 8 (4%) 48 (22–80) 71 (35%) 24 (10–34)
  Federal Government 94 7 (7%) 14 (13–24) 47 (50%) 17 (6–28)
  University 89 2 (2%) 51 (18–75) 49 (55%) 15 (6–27)
  Other 35 2 (6%) 16 (6–32) 16 (46%) 10 (1–28)
Trial Phase
  Phase I 59 1 (2%) 42 (16–49) 24 (41%) 17 (-4–40)
  Phase II 96 11 (12%) 25 (13–73) 43 (45%) 19 (5–28)
  Phase III 79 1 (1%) 43 (21–80) 23 (29%) 28 (18–34)
  Phase IV 54 1 (2%) 65 (24–85) 21 (39%) 19 (12–36)
  Other 45 1 (2%) 21 (14–79) 18 (40%) 18 (9–38)
Intervention Type
  Drug/biologic 44 0 (0%) 32 (19–59) 17 (39%) 19 (9–34)
  Vaccine 276 15 (5%) 43 (16–78) 108 (39%) 22 (9–34)
  Other 13 0 (0%)   4 (31%) 22 (13–48)
Recruiting Status in Registry
  Enrollment completed 286 15 (5%) 41 (16–76) 118 (41%) 21 (9–34)
  Enrollment not complete 11 0 (0%)   2 (18%) 41 (16–73)
  Stopped early 16 0 (0%) 49 (21–75) 2 (13%) 21 (7–41)
  Suspended/not currently enrolling 4 0 (0%)   1 (25%)  
  Unknown status 16 0 (0%)   6 (38%) 13 (5–25)